BRAF wild-type

BRAFV600E and TERT promoter co-mutation, identifiable preoperatively, defines a distinct PTC subtype with a profoundly aggressive clinicopathological profile and a significantly elevated risk of recurrence. This combined molecular signature is a potent preoperative biomarker for stratifying patients into the highest-risk category, potentially guiding more individualized initial therapeutic strategies.

Epinephrine or glial cell line-derived neurotrophic factor also stimulated migration specifically in BRAF-mutated cells. These results emphasize the importance of targeting specific neural signaling pathways and highlight that patient stratification is essential for cancer neuroscience studies.

P2, N=10, Not yet recruiting, Haihua Yuan

NF1 mutation is the strongest gene-level correlate of lung-selective metastasis in cutaneous melanoma. The NF1-mutant subtype may represent a dual-biomarker population and could warrant both pulmonary surveillance and prospective evaluation for immunotherapy.

Current evidence supports DNA methylation as a promising refinement biomarker, but not yet as a stand-alone decision tool. Prospective validation, assay standardization, and integration with ctDNA-guided resistance assessment are required before routine implementation.

P2, N=216, Completed, Melanoma Institute Australia | Trial completion date: Dec 2025 --> Mar 2026

P1, N=10, Not yet recruiting, West China Hospital

P=N/A, N=70, Not yet recruiting, Niguarda Hospital

Mechanistically, VEGF pathway inhibition may disrupt marrow endothelial integrity and hematopoietic homeostasis, promoting cytopenias and erythroid precursor release, while immune activation drives cytokine-mediated endothelial dysfunction and vascular hyperpermeability. Early recognition and prompt immunomodulatory management are critical to improving outcomes.

We report a 77-year-old woman with mCRC harboring a rare TIMM23B::RET fusion who achieved durable benefit from selpercatinib after progression on capecitabine. To our knowledge, this is among the first detailed reports of mCRC harboring a TIMM23B::RET fusion with documented clinical benefit from selpercatinib. This case highlights the value of comprehensive genomic profiling and individualized toxicity management in rare molecular subsets of mCRC.

In our IPD analysis, indirectly comparing three clinical trials, stop&go showed lower anti-EGFR skin-related toxicity versus maintenance. Shared decision-making, considering patient and tumor features and treatment tolerability, may allow defining optimal de-intensification strategy.

Adjuvant chemotherapy was classified as fluoropyrimidine monotherapy (5FU) or oxaliplatin-based therapy (Ox+)...Outcomes were similar between Ox+ and 5FU in double wild-type (KRAS and BRAF wild-type) tumors (OS HR = 1.11, 95% CI, 0.82-1.50). These findings suggest molecular heterogeneity in treatment associations that may inform adjuvant therapy selection.